“uncapping,” and cell death, and stimulates immune response when used sequentially with checkpoint inhibitor therapies. The company also runs a second-generation discovery program to generate novel telomere-targeting agents with improved specificity and anticancer activity. It has nominated molecular entity candidates (e.g. MAIA-2021-20, MAIA-2022-12) for preclinical development.